vs
CHIMERA INVESTMENT CORP（CIM）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
RIGEL PHARMACEUTICALS INC的季度营收约是CHIMERA INVESTMENT CORP的1.1倍（$69.8M vs $66.2M），RIGEL PHARMACEUTICALS INC净利率更高（384.0% vs 42.8%，领先341.2%），RIGEL PHARMACEUTICALS INC同比增速更快（21.2% vs 0.5%），过去两年RIGEL PHARMACEUTICALS INC的营收复合增速更高（53.7% vs 0.8%）
Chimera Investment Corp是一家总部位于美国的房地产投资信托，主要投资住宅抵押贷款支持证券、住宅及商业抵押贷款和其他房地产相关金融资产，聚焦为股东创造经风险调整的可持续回报，通过投资组合运营派发定期股息。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
CIM vs RIGL — 直观对比
营收规模更大
RIGL
是对方的1.1倍
$66.2M
营收增速更快
RIGL
高出20.7%
0.5%
净利率更高
RIGL
高出341.2%
42.8%
两年增速更快
RIGL
近两年复合增速
0.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $66.2M | $69.8M |
| 净利润 | $28.3M | $268.1M |
| 毛利率 | — | 91.5% |
| 营业利润率 | 42.6% | 33.2% |
| 净利率 | 42.8% | 384.0% |
| 营收同比 | 0.5% | 21.2% |
| 净利润同比 | 119.3% | 1769.2% |
| 每股收益（稀释后） | $0.05 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CIMRIGL
| Q4 25 | $66.2M | $69.8M | ||
| Q3 25 | $65.0M | $69.5M | ||
| Q2 25 | $66.0M | $101.7M | ||
| Q1 25 | $69.2M | $53.3M | ||
| Q4 24 | $65.8M | $57.6M | ||
| Q3 24 | $66.5M | $55.3M | ||
| Q2 24 | $67.3M | $36.8M | ||
| Q1 24 | $65.1M | $29.5M |
净利润CIMRIGL
| Q4 25 | $28.3M | $268.1M | ||
| Q3 25 | $-580.0K | $27.9M | ||
| Q2 25 | $35.5M | $59.6M | ||
| Q1 25 | $167.3M | $11.4M | ||
| Q4 24 | $-146.5M | $14.3M | ||
| Q3 24 | $136.5M | $12.4M | ||
| Q2 24 | $56.7M | $-1.0M | ||
| Q1 24 | $129.5M | $-8.2M |
毛利率CIMRIGL
| Q4 25 | — | 91.5% | ||
| Q3 25 | — | 93.2% | ||
| Q2 25 | — | 95.6% | ||
| Q1 25 | — | 91.7% | ||
| Q4 24 | — | 89.9% | ||
| Q3 24 | — | 85.5% | ||
| Q2 24 | — | 92.4% | ||
| Q1 24 | — | 93.1% |
营业利润率CIMRIGL
| Q4 25 | 42.6% | 33.2% | ||
| Q3 25 | -0.5% | 40.9% | ||
| Q2 25 | 54.3% | 60.1% | ||
| Q1 25 | — | 23.9% | ||
| Q4 24 | -222.6% | 28.9% | ||
| Q3 24 | — | 25.4% | ||
| Q2 24 | 84.2% | 1.2% | ||
| Q1 24 | — | -23.6% |
净利率CIMRIGL
| Q4 25 | 42.8% | 384.0% | ||
| Q3 25 | -0.9% | 40.2% | ||
| Q2 25 | 53.7% | 58.6% | ||
| Q1 25 | 241.7% | 21.5% | ||
| Q4 24 | -222.6% | 24.9% | ||
| Q3 24 | 205.4% | 22.5% | ||
| Q2 24 | 84.2% | -2.8% | ||
| Q1 24 | 198.8% | -27.9% |
每股收益（稀释后）CIMRIGL
| Q4 25 | $0.05 | $14.11 | ||
| Q3 25 | $-0.27 | $1.46 | ||
| Q2 25 | $0.17 | $3.28 | ||
| Q1 25 | $1.77 | $0.63 | ||
| Q4 24 | $-2.06 | $0.82 | ||
| Q3 24 | $1.39 | $0.70 | ||
| Q2 24 | $0.41 | $-0.06 | ||
| Q1 24 | $1.36 | $-0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $278.6M | $155.0M |
| 总债务越低越好 | $251.5M | $52.5M |
| 股东权益账面价值 | $2.6B | $391.5M |
| 总资产 | $15.8B | $513.6M |
| 负债/权益比越低杠杆越低 | 0.10× | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资CIMRIGL
| Q4 25 | $278.6M | $155.0M | ||
| Q3 25 | $491.5M | $137.1M | ||
| Q2 25 | $250.2M | $108.4M | ||
| Q1 25 | $253.3M | $77.1M | ||
| Q4 24 | $84.0M | $77.3M | ||
| Q3 24 | $97.3M | $61.1M | ||
| Q2 24 | $162.3M | $49.1M | ||
| Q1 24 | $169.0M | $49.5M |
总债务CIMRIGL
| Q4 25 | $251.5M | $52.5M | ||
| Q3 25 | $251.0M | $60.0M | ||
| Q2 25 | $135.2M | $60.0M | ||
| Q1 25 | $134.9M | $60.0M | ||
| Q4 24 | $134.6M | $60.0M | ||
| Q3 24 | $134.4M | $60.0M | ||
| Q2 24 | $62.4M | $60.0M | ||
| Q1 24 | — | $60.0M |
股东权益CIMRIGL
| Q4 25 | $2.6B | $391.5M | ||
| Q3 25 | $2.6B | $117.6M | ||
| Q2 25 | $2.6B | $81.9M | ||
| Q1 25 | $2.6B | $18.6M | ||
| Q4 24 | $2.5B | $3.3M | ||
| Q3 24 | $2.7B | $-14.6M | ||
| Q2 24 | $2.6B | $-29.9M | ||
| Q1 24 | $2.6B | $-31.7M |
总资产CIMRIGL
| Q4 25 | $15.8B | $513.6M | ||
| Q3 25 | $15.1B | $242.5M | ||
| Q2 25 | $14.9B | $206.7M | ||
| Q1 25 | $13.2B | $176.0M | ||
| Q4 24 | $13.1B | $164.0M | ||
| Q3 24 | $13.7B | $139.4M | ||
| Q2 24 | $13.1B | $128.4M | ||
| Q1 24 | $12.5B | $126.5M |
负债/权益比CIMRIGL
| Q4 25 | 0.10× | 0.13× | ||
| Q3 25 | 0.10× | 0.51× | ||
| Q2 25 | 0.05× | 0.73× | ||
| Q1 25 | 0.05× | 3.23× | ||
| Q4 24 | 0.05× | 18.25× | ||
| Q3 24 | 0.05× | — | ||
| Q2 24 | 0.02× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-248.9M | $22.0M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | -8.78× | 0.08× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CIMRIGL
| Q4 25 | $-248.9M | $22.0M | ||
| Q3 25 | $-137.5M | $24.0M | ||
| Q2 25 | $-7.4M | $30.5M | ||
| Q1 25 | $48.8M | $-893.0K | ||
| Q4 24 | $205.7M | $14.5M | ||
| Q3 24 | $41.4M | $21.7M | ||
| Q2 24 | $69.0M | $302.0K | ||
| Q1 24 | $57.3M | $-5.0M |
现金转化率CIMRIGL
| Q4 25 | -8.78× | 0.08× | ||
| Q3 25 | — | 0.86× | ||
| Q2 25 | -0.21× | 0.51× | ||
| Q1 25 | 0.29× | -0.08× | ||
| Q4 24 | — | 1.01× | ||
| Q3 24 | 0.30× | 1.75× | ||
| Q2 24 | 1.22× | — | ||
| Q1 24 | 0.44× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
